Grundium, a Tampere-based startup specialising in digital pathology imaging know-how, backed by US-based healthcare non-public fairness agency EW Healthcare Companions, has acquired Visiopharm, a Denmark-based supplier of AI-driven precision pathology software program.
The mixed enterprise merges complementary capabilities from Grundium’s imaging platform and Visiopharm’s AI-driven precision pathology software program, creating an accessible end-to-end answer for diagnostic laboratories, biopharmaceutical improvement, and analysis.
“Precision medication begins with precision pathology. By combining Grundium’s imaging applied sciences with Visiopharm’s superior AI functions, we’re making a stronger basis for physicians and laboratories to undertake high-value workflows and scale them over time. Collectively, we will help make precision pathology extra accessible, sensible, and impactful for patrons worldwide,” stated Mika Kuisma, CEO of Grundium.
Based in 2015 by former Nokia engineers, Kimmo Alanen, Mika Kuisma, and Janne Haavisto, Grundium develops compact, high-quality digital pathology scanners for healthcare, schooling, and analysis environments.
The corporate develops the Ocus® sequence of microscope scanners. Grundium states that these compact, high-precision gadgets make high-quality digital and distant pathology accessible to all, providing ease of use and affordability for labs of any measurement.
Based in 2002 by Michael Grunkin and Johan Doré Hansen, Visiopharm is on a mission to advance precision medication by reworking pathology via picture evaluation. It supplies an AI-driven precision pathology software program for analysis and diagnostics. In analysis, it claims to supply instruments that assist scientists, pathologists, and picture evaluation consultants produce correct knowledge for all sorts of tissue-based analysis.
In diagnostics, it specialises in scientific functions and has 9 diagnostic algorithms cleared below IVDR for EU clients. These functions present diagnostic choice help and could be simply activated and built-in into present lab workflows. Visiopharm operates internationally with over 750 buyer accounts in additional than 40 international locations.
“Grundium and Visiopharm deliver collectively extremely complementary capabilities. This mix permits us to attach biomarker evaluation, imaging, and high quality administration in new methods, whereas persevering with to help the software program and workflows our clients depend on in the present day. Collectively, we’re higher positioned to help the following section of precision diagnostics,” stated Michael Grunkin, CEO of Visiopharm
The mixed platform permits extra environment friendly, scalable digital pathology, whereas increasing entry via compact scanning options that decrease prices and take away infrastructure obstacles.
By combining Grundium’s scanner portfolio with Visiopharm’s AI-driven software program, the platform notes that it helps a broad vary of use circumstances, from particular person laboratory workflows to enterprise-scale deployments, biomarker improvement, translational analysis, scientific research, and companion diagnostic programmes.
Each corporations have beforehand collaborated by integrating their options for laboratories, and the acquisition strengthens this already established partnership.
“Digital pathology has the potential to drastically enhance diagnostic accuracy, workflow effectivity and world entry to knowledgeable care. The platform we’re creating brings these capabilities collectively to make prognosis sooner, extra dependable and extra environment friendly, reworking affected person care and supporting the event of latest breakthrough remedies, notably in oncology,” stated Andy Thomson, Working Companion at EW Healthcare Companions and Chair of the Board of Grundium.
To keep up continuity for present clients and companions, Grundium’s digital scanners and Visiopharm’s precision pathology software program will proceed to be supported and obtainable independently, enabling clients to proceed with their present options or to mix capabilities as their wants evolve.
